COVID-19 Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0D1HH
|
|||
Drug Name |
Carvedilol
|
|||
Synonyms |
Coreg; Dilatrend; Eucardic; Carvedilolum [Latin]; BM 14190; Carvedilolum; SKF 105517; BM-14190; Coreg CR; DQ 2466; HSDB 7044; DQ-2466
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Coronavirus Disease 2019 (COVID-19) | Investigative | [1] | |
Other Indication | Congestive heart failure | Approved | [2] | |
Therapeutic Class |
Antiviral Agents
|
|||
Structure |
Download2D MOL |
|||
Formula |
C24H26N2O4
|
|||
Canonical SMILES |
COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O
|
|||
InChI |
1S/C24H26N2O4/c1-28-21-10-4-5-11-22(21)29-14-13-25-15-17(27)16-30-23-12-6-9-20-24(23)18-7-2-3-8-19(18)26-20/h2-12,17,25-27H,13-16H2,1H3
|
|||
InChIKey |
OGHNVEJMJSYVRP-UHFFFAOYSA-N
|
|||
CAS Number |
CAS 72956-09-3
|
|||
PubChem Compound ID | ||||
ChEBI ID |
CHEBI:3441
|
Target | Top | |||
---|---|---|---|---|
Target(s) | HUMAN beta adrenergic receptor (BAR) | Target Info | Antagonist | [1] |
Carvedilol is a beta adrenergic receptor antagonist. Considering the potential role of beta-adrenergic blockers in decreasing the SARS-CoV-2 entry into the cells by downregulating ACE2 receptors, and its role in reducing the mortality in respiratory failure, ARDS and septic shock conditions, it is a good candidate drug for treating COVID-19 patients. |
References | Top | |||
---|---|---|---|---|
1 | Can beta-adrenergic blockers be used in the treatment of COVID-19 Med Hypotheses. 2020 May 5;142:109809. | |||
2 | FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (ANDA) 078332. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.